Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021
Anika Therapeutics (NASDAQ: ANIK) will release its fourth quarter and year-end 2020 financial results after market close on March 4, 2021. An investor conference call will follow at 5:00 p.m. ET to discuss these results and business highlights. Interested parties can access the call by dialing the provided numbers or via a live audio webcast available on Anika's Investor Relations page. The call will be archived for later access.
- Upcoming financial results announcement on March 4, 2021.
- Opportunity for investors to engage in discussion regarding financial performance.
- None.
BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end 2020 financial results after the close of the market on Thursday, March 4, 2021 and hold its investor conference call and webcast on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10012940. A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika investor relations website. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com.
For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Executive Director, Investor Relations and Corporate Communications
investorrelations@anika.com
FAQ
When will Anika Therapeutics release its fourth quarter results?
What time is Anika Therapeutics' investor conference call?
How can I access Anika Therapeutics' earnings call?